Kezar Life Sciences, Inc. (KZR)
7.29
0.00 (0.00%)
USD |
NASDAQ |
Jun 09, 16:00
Kezar Life Sciences SG&A Expense (Quarterly) : 5.208M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| NovelStem International Corp. | 0.005M |
| Brainstorm Cell Therapeutics, Inc. | 1.284M |
| Summit Therapeutics, Inc. | 62.59M |
| Protara Therapeutics, Inc. | 6.067M |
| Clene, Inc. | 1.747M |